FDA questions Amgen drug for prostate cancer
Save Email Print
Bookmark and Share
Updated: 4:16 PM Feb 6, 2012
FDA questions Amgen drug for prostate cancer
Scientists for the Food and Drug Administration say an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug failed to extend life and carried significant side effects.
Posted: 11:42 AM Feb 6, 2012
Reporter: The Associated Press
Email Address: katherine.rufener@wndu.com
Font Size:

Scientists for the Food and Drug Administration say an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug failed to extend life and carried significant side effects.

The Food and Drug Administration will ask a panel of outside experts on Wednesday whether the benefits of Amgen's Xgeva outweigh its risks, which included bone disease in about 5 percent of patients taking the drug.

Xgeva is already approved for preventing fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.

Now Amgen has asked the FDA to approve its injectable drug for men with recurring prostate cancer that is at high risk of spreading to the bone. Men must have also attempted and failed treatment with hormone therapy.
More Stories

WNDU News Poll
There are currently no active polls at this time.
Click here to view other polls on our site and past poll results.
Most Popular Headlines